- Conditions
- Depression, Anxious Depression, Major Depressive Disorder
- Interventions
- Ketamine, Magnetic Resonance Imaging (MRI)
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 104
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Tobacco Use, Smoking Cessation, Nicotine Dependence
- Interventions
- Ketamine Hydrochloride, Motivational enhancement therapy
- Drug · Behavioral
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Major Depressive Disorder
- Interventions
- Lithium, Ketamine
- Drug
- Lead sponsor
- James Murrough
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cancer, Pain
- Interventions
- Intranasal ketamine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Suicidal Ideation, Suicide
- Interventions
- Ketamine Hydrochloride
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Bipolar Depression, Suicidal Ideation
- Interventions
- Ketamine Hydrochloride, Placebo
- Drug
- Lead sponsor
- NeuroRx, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Hollywood, Florida • Fort Worth, Texas
- Conditions
- Pruritus
- Interventions
- Ketamine Hydrochloride, Amitriptyline Hydrochloride, Lidocaine Hydrochloride, Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride, Lipoderm Cream
- Drug · Combination Product
- Lead sponsor
- Gil Yosipovitch
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Major Depressive Disorder
- Interventions
- (2R,6R)-Hydroxynorketamine hydrochloride, Placebo
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Treatment-resistant Depression
- Interventions
- ketamine, midazolam
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Bipolar Disorder
- Interventions
- Standard of Care, Ketamine, D-cycloserine
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Treatment-resistant Depression
- Interventions
- Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
- Conditions
- Substance Use Disorders, Substance Use, Methamphetamine Abuse
- Interventions
- Ketamine Hydrochloride, Midazolam Hydrochloride
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- San Leandro, California • Albuquerque, New Mexico • New York, New York + 2 more
- Conditions
- Treatment Resistant Depression
- Interventions
- Ketamine
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neuropathic Pain, PTSD
- Interventions
- Ketamine, Magnesium sulfate, Ketamine + Magnesium sulfate
- Drug
- Lead sponsor
- Margaux M. Salas, PhD
- Federal
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- baclofen/amitriptyline/ketamine gel, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 165
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 104 more
- Conditions
- Treatment-resistant Depression
- Interventions
- Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 802 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 16
- States / cities
- New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
- Conditions
- Treatment-resistant Depression
- Interventions
- Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Ketamine, Exposure and Response Prevention
- Drug · Behavioral
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- Ketamine Hydrochloride
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy Controls
- Interventions
- Ketamine, Normal saline
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 3
- States / cities
- Sacramento, California • New Haven, Connecticut • New York, New York
- Conditions
- Depressive Disorder, Major, Suicidal
- Interventions
- SLS-002, Placebo, Standard of care, Intranasal device
- Drug · Other · Device
- Lead sponsor
- Seelos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 21
- States / cities
- Orange, California • Panorama City, California • San Diego, California + 18 more
- Conditions
- Traumatic Injury
- Interventions
- Ketamine Hydrochloride, Fentanyl Citrate
- Drug
- Lead sponsor
- Jason Sperry
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 994 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 11
- States / cities
- San Diego, California • San Francisco, California • Camden, New Jersey + 7 more
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Intranasal Ketamine, Intranasal Midazolam
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Postoperative Quality of Recovery
- Interventions
- Opioid Free Total Intravenous Anesthesia, Total Intravenous anesthesia with opioid
- Combination Product
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Manhasset, New York